Literature DB >> 24338345

Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults.

Jonathan I Bisson1, Neil P Roberts, Martin Andrew, Rosalind Cooper, Catrin Lewis.   

Abstract

BACKGROUND: Post-traumatic stress disorder (PTSD) is a distressing condition, which is often treated with psychological therapies. Earlier versions of this review, and other meta-analyses, have found these to be effective, with trauma-focused treatments being more effective than non-trauma-focused treatments. This is an update of a Cochrane review first published in 2005 and updated in 2007.
OBJECTIVES: To assess the effects of psychological therapies for the treatment of adults with chronic post-traumatic stress disorder (PTSD). SEARCH
METHODS: For this update, we searched the Cochrane Depression, Anxiety and Neurosis Group's Specialised Register (CCDANCTR-Studies and CCDANCTR-References) all years to 12th April 2013. This register contains relevant randomised controlled trials from: The Cochrane Library (all years), MEDLINE (1950 to date), EMBASE (1974 to date), and PsycINFO (1967 to date). In addition, we handsearched the Journal of Traumatic Stress, contacted experts in the field, searched bibliographies of included studies, and performed citation searches of identified articles. SELECTION CRITERIA: Randomised controlled trials of individual trauma-focused cognitive behavioural therapy (TFCBT), eye movement desensitisation and reprocessing (EMDR), non-trauma-focused CBT (non-TFCBT), other therapies (supportive therapy, non-directive counselling, psychodynamic therapy and present-centred therapy), group TFCBT, or group non-TFCBT, compared to one another or to a waitlist or usual care group for the treatment of chronic PTSD. The primary outcome measure was the severity of clinician-rated traumatic-stress symptoms. DATA COLLECTION AND ANALYSIS: We extracted data and entered them into Review Manager 5 software. We contacted authors to obtain missing data. Two review authors independently performed 'Risk of bias' assessments. We pooled the data where appropriate, and analysed for summary effects. MAIN
RESULTS: We include 70 studies involving a total of 4761 participants in the review. The first primary outcome for this review was reduction in the severity of PTSD symptoms, using a standardised measure rated by a clinician. For this outcome, individual TFCBT and EMDR were more effective than waitlist/usual care (standardised mean difference (SMD) -1.62; 95% CI -2.03 to -1.21; 28 studies; n = 1256 and SMD -1.17; 95% CI -2.04 to -0.30; 6 studies; n = 183 respectively). There was no statistically significant difference between individual TFCBT, EMDR and Stress Management (SM) immediately post-treatment although there was some evidence that individual TFCBT and EMDR were superior to non-TFCBT at follow-up, and that individual TFCBT, EMDR and non-TFCBT were more effective than other therapies. Non-TFCBT was more effective than waitlist/usual care and other therapies. Other therapies were superior to waitlist/usual care control as was group TFCBT. There was some evidence of greater drop-out (the second primary outcome for this review) in active treatment groups. Many of the studies were rated as being at 'high' or 'unclear' risk of bias in multiple domains, and there was considerable unexplained heterogeneity; in addition, we assessed the quality of the evidence for each comparison as very low. As such, the findings of this review should be interpreted with caution. AUTHORS'
CONCLUSIONS: The evidence for each of the comparisons made in this review was assessed as very low quality. This evidence showed that individual TFCBT and EMDR did better than waitlist/usual care in reducing clinician-assessed PTSD symptoms. There was evidence that individual TFCBT, EMDR and non-TFCBT are equally effective immediately post-treatment in the treatment of PTSD. There was some evidence that TFCBT and EMDR are superior to non-TFCBT between one to four months following treatment, and also that individual TFCBT, EMDR and non-TFCBT are more effective than other therapies. There was evidence of greater drop-out in active treatment groups. Although a substantial number of studies were included in the review, the conclusions are compromised by methodological issues evident in some. Sample sizes were small, and it is apparent that many of the studies were underpowered. There were limited follow-up data, which compromises conclusions regarding the long-term effects of psychological treatment.

Entities:  

Mesh:

Year:  2013        PMID: 24338345      PMCID: PMC6991463          DOI: 10.1002/14651858.CD003388.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  129 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  A randomized trial of a reconciliation workshop with and without PTSD psychoeducation in Burundian sample.

Authors:  Peter D Yeomans; Evan M Forman; James D Herbert; Erica Yuen
Journal:  J Trauma Stress       Date:  2010-06

3.  Supportive-expressive group therapy and distress in patients with metastatic breast cancer: a randomized clinical intervention trial.

Authors:  C Classen; L D Butler; C Koopman; E Miller; S DiMiceli; J Giese-Davis; P Fobair; R W Carlson; H C Kraemer; D Spiegel
Journal:  Arch Gen Psychiatry       Date:  2001-05

4.  Psychological treatment of chronic posttraumatic stress disorder in victims of sexual aggression.

Authors:  E Echeburúa; P de Corral; I Zubizarreta; B Sarasua
Journal:  Behav Modif       Date:  1997-10

5.  Issues in the design of multisite clinical trials of psychotherapy: VA Cooperative Study No. 494 as an example.

Authors:  Paula P Schnurr; Matthew J Friedman; Charles C Engel; Edna B Foa; M Tracie Shea; Patricia M Resick; Kenneth E James; Bruce K Chow
Journal:  Contemp Clin Trials       Date:  2005-10-19       Impact factor: 2.226

6.  Treating low-income and minority women with posttraumatic stress disorder: a pilot study comparing prolonged exposure and treatment as usual conducted by community therapists.

Authors:  Ulrike Feske
Journal:  J Interpers Violence       Date:  2008-02-21

7.  Post-traumatic stress disorder in the context of terrorism and other civil conflict in Northern Ireland: randomised controlled trial.

Authors:  Michael Duffy; Kate Gillespie; David M Clark
Journal:  BMJ       Date:  2007-05-11

8.  A randomized trial of self-management and psychoeducational group therapies for comorbid chronic posttraumatic stress disorder and depressive disorder.

Authors:  Nancy Jo Dunn; Lynn P Rehm; Jeanne Schillaci; Julianne Souchek; Paras Mehta; Carol M Ashton; Elisia Yanasak; Joseph D Hamilton
Journal:  J Trauma Stress       Date:  2007-06

9.  How well does cognitive-behavioral therapy treat symptoms of complex PTSD? An examination of child sexual abuse survivors within a clinical trial.

Authors:  Patricia A Resick; Pallavi Nishith; Michael G Griffin
Journal:  CNS Spectr       Date:  2003-05       Impact factor: 3.790

10.  Posttraumatic stress disorder in the National Comorbidity Survey.

Authors:  R C Kessler; A Sonnega; E Bromet; M Hughes; C B Nelson
Journal:  Arch Gen Psychiatry       Date:  1995-12
View more
  157 in total

1.  A Randomized, Controlled Trial of Wholistic Hybrid Derived From Eye Movement Desensitization and Reprocessing and Emotional Freedom Technique (WHEE) for Self-Treatment of Pain, Depression, and Anxiety in Chronic Pain Patients.

Authors:  Daniel Benor; John Rossiter-Thornton; Loren Toussaint
Journal:  J Evid Based Complementary Altern Med       Date:  2016-07-20

2.  Relations Between Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-Exposed Military Veterans With Alcohol Use Disorder.

Authors:  Adrienne J Heinz; David L Pennington; Nicole Cohen; Brandi Schmeling; Brooke A Lasher; Emily Schrodek; Steven L Batki
Journal:  Mil Med       Date:  2016-07       Impact factor: 1.437

3.  Examination of Racial Differences in a Posttraumatic Stress Disorder Group Therapy Program for Veterans.

Authors:  Jennifer A Coleman; John R Lynch; Kathleen M Ingram; Christina M Sheerin; Lance M Rappaport; Stephen K Trapp
Journal:  Group Dyn       Date:  2018-07-19

4.  Multiple session early psychological interventions for the prevention of post-traumatic stress disorder.

Authors:  Neil P Roberts; Neil J Kitchiner; Justin Kenardy; Lindsay Robertson; Catrin Lewis; Jonathan I Bisson
Journal:  Cochrane Database Syst Rev       Date:  2019-08-08

Review 5.  [Psychosomatics and psychotraumatology of refugees and migrants : A Challenge for the Internist].

Authors:  J Schellong; F Epple; K Weidner
Journal:  Internist (Berl)       Date:  2016-05       Impact factor: 0.743

6.  Treating nightmares--sleep medicine and posttraumatic stress disorder.

Authors:  James F Pagel
Journal:  J Clin Sleep Med       Date:  2015-01-15       Impact factor: 4.062

Review 7.  [Posttraumatic stress disorder after intensive care : Prevalence, risk factors, and treatment].

Authors:  R Gawlytta; G-B Wintermann; M Böttche; H Niemeyer; C Knaevelsrud; J Rosendahl
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-03-03       Impact factor: 0.840

8.  The glucocorticoid receptor-FKBP51 complex contributes to fear conditioning and posttraumatic stress disorder.

Authors:  Haiyin Li; Ping Su; Terence Ky Lai; Anlong Jiang; Jing Liu; Dongxu Zhai; Charlie Tg Campbell; Frankie Hf Lee; WeiDong Yong; Suvercha Pasricha; Shupeng Li; Albert Hc Wong; Kerry J Ressler; Fang Liu
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

9.  Trauma, treatment and Tetris: video gaming increases hippocampal volume in male patients with combat-related posttraumatic stress disorder.

Authors:  Oisin Butler; Kerstin Herr; Gerd Willmund; Jürgen Gallinat; Simone Kühn; Peter Zimmermann
Journal:  J Psychiatry Neurosci       Date:  2020-07-01       Impact factor: 6.186

10.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.